Vimian Group AB
STO:VIMIAN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7617
46.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vimian Group AB
Total Receivables
Vimian Group AB
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Total Receivables
€153.6m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Total Receivables
kr25.8m
|
CAGR 3-Years
48%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Total Receivables
kr188m
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
32%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Total Receivables
kr23.7m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
61%
|
CAGR 10-Years
24%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Total Receivables
kr30.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Total Receivables
kr1.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Vimian Group AB
Glance View
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm and currently employs 1,068 full-time employees. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
See Also
What is Vimian Group AB's Total Receivables?
Total Receivables
153.6m
EUR
Based on the financial report for Sep 30, 2024, Vimian Group AB's Total Receivables amounts to 153.6m EUR.
What is Vimian Group AB's Total Receivables growth rate?
Total Receivables CAGR 3Y
67%
Over the last year, the Total Receivables growth was 181%. The average annual Total Receivables growth rates for Vimian Group AB have been 67% over the past three years .
You don't have any saved screeners yet
